the failed osteoporosis drug that became a bodybuilding staple
1995-1996 (chemistry published; receptor cloned) — broader arc 1977-1999
Merck's chemists built a drug that perfectly fit a lock three years before anyone on Earth knew what the key looked like.
The story of MK-677 begins not in a corporate lab but at Tulane University in 1977, where endocrinologist Cyril Bowers and chemist Frank Momany stumbled onto something strange: synthetic peptides that looked chemically like opioids but triggered a sudden burst of growth hormone with none of the opioid effects. Over the next seven years they honed the discovery into GHRP-6 (1984), the first peptide purpose-built to make the pituitary gland dump growth hormone on command. The catch was that nobody knew how it worked — what receptor it grabbed, or what natural hormone normally pulled the same trigger. It was, in the truest sense, a key with no known lock.
In the early 1990s, Merck's medicinal chemistry group in Rahway, New Jersey, picked up the thread with a very practical goal: turn Bowers' injectable peptide into a pill you could swallow. Working backward from GHRP-6 in a classic feat of 'reverse pharmacology,' Patchett, Smith, and colleagues engineered a non-peptide spiroindoline compound, published in 1995 (PNAS) as MK-0677 — orally active, once-daily, and just as potent in animals. Then came the twist that still turns heads: in 1996, Merck scientists (Howard et al., Science) used MK-677 itself as a molecular probe to clone the receptor it was hitting — an 'orphan' receptor with no known natural partner. Merck owned a finished, patented drug docked onto that receptor for three full years before anyone identified the body's own signal for it: ghrelin, the stomach's now-famous 'hunger hormone,' finally isolated in 1999 by Kojima and colleagues in Japan (Nature), who built directly on the receptor Merck's program had already mapped.
On paper, MK-677 looked like the oral anti-frailty pill an aging world was waiting for. Human trials led largely by endocrinologist Michael Thorner at the University of Virginia showed it reliably restored youthful growth-hormone and IGF-1 levels in elderly subjects, deepened sleep, built lean mass, and even reversed diet-induced muscle wasting in healthy volunteers (JCEM, 1997–1998). But the promise curdled: the extra muscle came without the payoff that mattered — no better grip strength, no better mobility — a verdict later nailed down by a 2008 Annals of Internal Medicine trial (Nass, Thorner et al.), and Merck stepped back from its anti-frailty ambitions around 1999. The door was shut for good more than a decade later, when a hip-fracture trial (Adunsky et al., 2011) flagged more congestive-heart-failure events in treated patients than placebo, plus worsened insulin resistance and fluid retention. MK-677 never had an NDA filed, and never won FDA approval.
The jaw-dropping core of this story holds up beautifully — three separate peer-reviewed papers confirm that Merck had a finished drug sitting on its receptor for three years before anyone found the body's matching hormone. What's embellished is the tidy timeline of Merck's exit: the famous hip-fracture heart-failure trial wasn't published until 2011, roughly a decade after the company had already stepped back, so it couldn't have been the single cause of a clean late-1990s shutdown.
Ibutamoren remains, formally, an unapproved investigational drug — no country has ever licensed it for human use. In the US it's legal to possess (it isn't DEA-scheduled) but banned by WADA/USADA for any tested athlete, and it is not a legal dietary-supplement ingredient despite being marketed like one; it circulates almost entirely through unregulated vendors with no purity guarantees. The more interesting new chapter is that the same molecule has been revived as LUM-201 by Lumos Pharma, now in Phase 2/3 trials for pediatric growth-hormone deficiency — the exact drug Merck walked away from a quarter-century ago is working its way back toward the FDA approval it never got, this time for a far narrower and more defensible patient group than the one that sank it in the 1990s.
That should have been the end of the story. Instead, the very thing that made MK-677 attractive to Merck — a pill, no needles, no reconstitution, no refrigerated vials — made it perfect for the gray market. Through the 2000s and 2010s it drifted onto bodybuilding and biohacking forums under the name ibutamoren, sold as a 'research chemical' rather than a drug: not scheduled by the DEA, banned by WADA for tested athletes, but with essentially no barrier to a private buyer ordering it online.
